Cadence Pharmaceuticals–Mallinckrodt: investment, 201402 acquisition $1.3b cash tender offer by Mallinkcrodt plc

	Period	2014-02-11
	Money taker	Cadence Pharmaceuticals Inc.
	Today	Mallinckrodt (Group)
	Group	Mallinckrodt (Group)
	Money source	Mallinckrodt plc (NYSE: MNK)
	Group	Mallinckrodt (Group)
	Product	Ofirmev®
	Product 2	pharmaceutical

Record changed: 2024-03-24

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Mallinckrodt (Group)

[1] Silence Therapeutics plc. (7/18/19). "Press Release: Silence Therapeutics and Mallinckrodt Announce Collaboration to Develop and Commercialize RNAi Therapeutics for Complement-mediated Diseases". London & Staines-upon-Thames....
[2] Silence Therapeutics plc. (7/18/19). "Press Release: Mallinckrodt to Make an Equity Investment in Silence Therapeutics as Part of a Collaboration". London & Staines-upon-Thames....
[3] Pieris Pharmaceuticals, Inc.. (9/10/18). "Press Release: Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil., to its Board of Directors". Boston, MA....
[4] Mallinckrodt plc. (12/26/17). "Press Release: Mallinckrodt to Acquire Sucampo Pharmaceuticals for approximately $1.2 Billion". Staines-upon-Thames & Rockville, MD....
[5] Mallinckrodt plc. (12/8/17). "Press Release: Mallinckrodt to Present at 36th Annual J.P. Morgan Healthcare Conference". Staines-upon-Thames....
[6] Goodwin Procter LLP. (11/2/17). "Press Release: Ocera Therapeutics Acquired by Mallinckrodt for $42 Million"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]